CEO Monthly April 2017

CEO MONTHLY / APRIL 2017 31 , UnitedBioMedical (UBI) is aprivately-heldmultinational biopharmaceutical companydedicated to the discovery, development and commercializationof immunotherapeutics andvaccines for chronic and infectious diseases.We profileCo-Founder andCEOof thefirm’s Asian companyDr ChangYiWang, exploringhowshehas helped lead thefirmto the success it is today. Ahead of the Curve on Immunology BI’s product pipeline is filled with a new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases, highlighting the firm’s dedication to supporting patients. These products are based on our proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. The firm’s platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire. UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by the firm’s subsidiary UBI-Asia and various sponsorships in product development. UBI-Asia’s CEO Dr Chang Yi Wang has been a Chairperson on the firm’s Board of Directors since 1998, and is now the Chairperson and CEO of UBI- Asia. Dr. Wang is the principal inventor of over 80 of UBI’s issued patents and patent applications. Under her direction, the UBITh platform technology was developed. She has published more than 120 peer reviewed scientific papers and has been invited to give plenary lectures in the areas of immunology, vaccination, immunotherapeutics and infectious diseases. She also serves on the US NIH scientific review committee for the “Cooperative Research Partnerships for BioDefense” funding program and the SBIR Immunobiology and Allergy funding program. In 2007 Dr. Wang received the Inventor of the Year Award from the New York Intellectual Property Law Association (NYPLA). From 1981 to 1985, Dr. Wang was a principal investigator and head of the Laboratory of Molecular Immunology at the Memorial Sloan-Kettering Cancer Center in New York and a faculty member of the Department of Immunology, Sloan-Kettering Division, Cornell University Medical School. Dr. Wang received her B.S. degree in Chemistry from National Taiwan University and her Ph.D. degree in Immunology and Biochemistry from The Rockefeller University, New York. Dr. Wang has been a pioneer in following a path with the concept of “Immunology as a secret weapon of medicine,” combined with a powerful motivation to develop medical interventions through the application of basic biomedical sciences. Her first applications and inventions in the field of immunological applications of Synthetic peptide were antibody screening immunoassays employing highly optimized synthetic viral peptide antigens. First was the development of a synthetic peptide based HIV 1 test and later an HIV 1,2 diagnostic test for blood screening, which received U.S. Food and Drug Administration approvals in 1989 and 1996, respectively. These tests were subsequently approved by WHO as suitable for worldwide use. Her other inventions in this area include synthetic peptide-based blood screening diagnostics for HTLV I/ II, HCV Hepatitis C virus, which has CE certification and has been sold in the global market through Organon Teknika / Biomerieux since 1991, and the SARS Coronavirus, as well as diagnostic tests for the differentiation of infected vs. vaccinated animals for Foot and mouth disease. Since 1992, she has been encouraged by the support and guidance of Dr. James D. Watson, the co- discoverer of the double-helix structure of DNA Double helix structure in the courageous pursuit of many challenging vaccine and immunotherapeutic programs employing designer synthetic peptides Synthetic peptide. Dr. Wang’s United Biomedical, Inc. also received Bill and Melinda Gates Foundation Grand Challenges Explorations grant for a new approach to an AIDS vaccine. Currently, UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. A second designer peptdie vaccine for immunocastration has gained product regulatory approvals as first class new biologics in Taiwan, Mexico and Brazil with many more to follow moving forward.